López, Carlos López http://orcid.org/0000-0002-8901-741X
Calvo, Mariona
Cámara, Juan Carlos
García-Paredes, Beatriz
Gómez-Martin, Carlos
López, Ana María
Pazo-Cid, Roberto
Sastre, Javier
Yaya, Ricardo
Feliu, Jaime
Article History
Accepted: 11 June 2024
First Online: 24 June 2024
Declarations
:
: CLL reports Advisory Board—Speaker from Lilly, Roche, AstraZeneca, Bayer, Eisai, Ipsen MSD and BMS. BGP reports Advisory Board—Speaker from Roche Farma, Eisai and Advanced Accelerator Applications<b>;</b> Speaker from BMS, Bayer and Lilly<b>;</b> Advisory Board—Speaker—Other from MSD, Amgen and Servier and Speaker—Other from Sanofi-Aventis, Merck and Ipsen. RPC reports Advisory Board—Speaker from Amgen and AstraZeneca<b>;</b> Advisory Board—Speaker—Grant—Personal Feels from Astellas, BMS and F. Hoffmann-La Roche<b>;</b> Grant from Beigene and Celgene<b>;</b> Speaker from Eisai<b>;</b> Speaker—Personal Feels from Eli Lilly<b>;</b> Advisory Board—Speaker—Grant from Ipsen and Advisory Board—Grant from Servier, JF reports Advisory Board from Roche Pharma, AstraZeneca, Eisai, Merck, Viatris and Baxter<b>;</b> Advisory Board—Grant from Amgen and Speaker from Servier. MCC, JJC, CGM, AML, JS, RY have nothing to disclose.
: The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.